## Claudia Balducci

## List of Publications by Citations

Source: https://exaly.com/author-pdf/4249131/claudia-balducci-publications-by-citations.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

62 2,929 32 53 h-index g-index citations papers 66 6.4 5.17 3,399 avg, IF L-index ext. citations ext. papers

#	Paper	IF	Citations
62	Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2010</b> , 107, 229	5 <del>13</del> 00	371
61	Reduced anxiety and improved stress coping ability in mice lacking NPY-Y2 receptors. <i>European Journal of Neuroscience</i> , <b>2003</b> , 18, 143-8	3.5	158
60	Dissociable contribution of 5-HT1A and 5-HT2A receptors in the medial prefrontal cortex to different aspects of executive control such as impulsivity and compulsive perseveration in rats. <i>Neuropsychopharmacology</i> , <b>2006</b> , 31, 757-67	8.7	150
59	An N-terminal fragment of the prion protein binds to amyloid-lbligomers and inhibits their neurotoxicity in vivo. <i>Journal of Biological Chemistry</i> , <b>2013</b> , 288, 7857-7866	5.4	142
58	Neuropeptide Y gene therapy decreases chronic spontaneous seizures in a rat model of temporal lobe epilepsy. <i>Brain</i> , <b>2008</b> , 131, 1506-15	11.2	134
57	Multifunctional liposomes reduce brain Eamyloid burden and ameliorate memory impairment in Alzheimer's disease mouse models. <i>Journal of Neuroscience</i> , <b>2014</b> , 34, 14022-31	6.6	112
56	Alzheimer's Disease, Oligomers, and Inflammation. <i>Journal of Alzheimerrs Disease</i> , <b>2018</b> , 62, 1261-1276	4.3	89
55	Toll-like receptor 4-dependent glial cell activation mediates the impairment in memory establishment induced by Emyloid oligomers in an acute mouse model of Alzheimer's disease. <i>Brain, Behavior, and Immunity</i> , <b>2017</b> , 60, 188-197	16.6	87
54	The serotonin 5-HT2A receptors antagonist M100907 prevents impairment in attentional performance by NMDA receptor blockade in the rat prefrontal cortex. <i>Neuropsychopharmacology</i> , <b>2004</b> , 29, 1637-47	8.7	86
53	Mutant prion protein expression causes motor and memory deficits and abnormal sleep patterns in a transgenic mouse model. <i>Neuron</i> , <b>2008</b> , 60, 598-609	13.9	80
52	Time-dependent induction of anxiogenic-like effects after central infusion of urocortin or corticotropin-releasing factor in the rat. <i>Psychopharmacology</i> , <b>2002</b> , 160, 113-21	4.7	69
51	Antibody-functionalized polymer nanoparticle leading to memory recovery in Alzheimer's disease-like transgenic mouse model. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , <b>2018</b> , 14, 609-618	6	67
50	Oligomeropathies and pathogenesis of Alzheimer and Parkinson's diseases. <i>Movement Disorders</i> , <b>2016</b> , 31, 771-81	7	66
49	c-Jun N-terminal kinase regulates soluble Albligomers and cognitive impairment in AD mouse model. <i>Journal of Biological Chemistry</i> , <b>2011</b> , 286, 43871-43880	5.4	65
48	Blocking ADAM10 synaptic trafficking generates a model of sporadic Alzheimer's disease. <i>Brain</i> , <b>2010</b> , 133, 3323-35	11.2	57
47	Neuroinflammation and the Gut Microbiota: Possible Alternative Therapeutic Targets to Counteract Alzheimer's Disease?. <i>Frontiers in Aging Neuroscience</i> , <b>2019</b> , 11, 284	5.3	56
46	Anticonvulsant effects and behavioural outcomes of rAAV serotype 1 vector-mediated neuropeptide Y overexpression in rat hippocampus. <i>Gene Therapy</i> , <b>2010</b> , 17, 643-52	4	56

45	APP transgenic mice: their use and limitations. NeuroMolecular Medicine, 2011, 13, 117-37	4.6	54
44	NPY gene transfer in the hippocampus attenuates synaptic plasticity and learning. <i>Hippocampus</i> , <b>2008</b> , 18, 564-74	3.5	47
43	In vivo application of beta amyloid oligomers: a simple tool to evaluate mechanisms of action and new therapeutic approaches. <i>Current Pharmaceutical Design</i> , <b>2014</b> , 20, 2491-505	3.3	47
42	Transgenic fatal familial insomnia mice indicate prion infectivity-independent mechanisms of pathogenesis and phenotypic expression of disease. <i>PLoS Pathogens</i> , <b>2015</b> , 11, e1004796	7.6	45
41	The Becretase modulator CHF5074 restores memory and hippocampal synaptic plasticity in plaque-free Tg2576 mice. <i>Journal of Alzheimerrs Disease</i> , <b>2011</b> , 24, 799-816	4.3	44
40	Dextromethorphan reduces intravenous cocaine self-administration in the rat. <i>European Journal of Pharmacology</i> , <b>1997</b> , 321, 279-83	5.3	44
39	WAY 100635, a 5-HT1A receptor antagonist, prevents the impairment of spatial learning caused by blockade of hippocampal NMDA receptors. <i>Neuropharmacology</i> , <b>1999</b> , 38, 1165-73	5.5	41
38	Alpha-synuclein oligomers impair memory through glial cell activation and via Toll-like receptor 2. <i>Brain, Behavior, and Immunity</i> , <b>2018</b> , 69, 591-602	16.6	40
37	Retro-inverso peptide inhibitor nanoparticles as potent inhibitors of aggregation of the Alzheimer's Alþeptide. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , <b>2017</b> , 13, 723-732	6	39
36	Cognitive deficits associated with alteration of synaptic metaplasticity precede plaque deposition in APP23 transgenic mice. <i>Journal of Alzheimerrs Disease</i> , <b>2010</b> , 21, 1367-81	4.3	34
35	Low doses of 8-OH-DPAT prevent the impairment of spatial learning caused by intrahippocampal scopolamine through 5-HT(1A) receptors in the dorsal raphe. <i>British Journal of Pharmacology</i> , <b>2000</b> , 131, 375-81	8.6	33
34	S 15535, a benzodioxopiperazine acting as presynaptic agonist and postsynaptic 5-HT1A receptor antagonist, prevents the impairment of spatial learning caused by intrahippocampal scopolamine. <i>British Journal of Pharmacology</i> , <b>1999</b> , 128, 1207-14	8.6	33
33	Exploring Alzheimer's disease mouse brain through X-ray phase contrast tomography: From the cell to the organ. <i>NeuroImage</i> , <b>2019</b> , 184, 490-495	7.9	33
32	Doxycycline for Alzheimer's Disease: Fighting EAmyloid Oligomers and Neuroinflammation. <i>Frontiers in Pharmacology</i> , <b>2019</b> , 10, 738	5.6	32
31	Reversal of visual attention dysfunction after AMPA lesions of the nucleus basalis magnocellularis (NBM) by the cholinesterase inhibitor donepezil and by a 5-HT1A receptor antagonist WAY 100635. <i>Psychopharmacology</i> , <b>2003</b> , 167, 28-36	4.7	32
30	Novel targets in Alzheimer's disease: A special focus on microglia. <i>Pharmacological Research</i> , <b>2018</b> , 130, 402-413	10.2	31
29	Doxycycline counteracts neuroinflammation restoring memory in Alzheimer's disease mouse models. <i>Neurobiology of Aging</i> , <b>2018</b> , 70, 128-139	5.6	31
28	Neuropeptide Y overexpression using recombinant adeno-associated viral vectors.  Neurotherapeutics, 2009, 6, 300-6	6.4	31

27	Inhibition of nitric oxide synthesis reduces intravenous cocaine self-administration in the rat. <i>Neuropharmacology</i> , <b>1996</b> , 35, 1811-4	5.5	28
26	Plasma and Brain Concentrations of Doxycycline after Single and Repeated Doses in Wild-Type and APP23 Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2019</b> , 368, 32-40	4.7	28
25	Cellular prion protein neither binds to alpha-synuclein oligomers nor mediates their detrimental effects. <i>Brain</i> , <b>2019</b> , 142, 249-254	11.2	27
24	Multifunctional liposomes delay phenotype progression and prevent memory impairment in a presymptomatic stage mouse model of Alzheimer disease. <i>Journal of Controlled Release</i> , <b>2017</b> , 258, 12	1-129	26
23	Striatum and entorhinal cortex atrophy in AD mouse models: MRI comprehensive analysis. <i>Neurobiology of Aging</i> , <b>2015</b> , 36, 776-88	5.6	23
22	Stimulation of 5-HT(1A) receptors in the dorsal raphe ameliorates the impairment of spatial learning caused by intrahippocampal 7-chloro-kynurenic acid in naive and pretrained rats. <i>Psychopharmacology</i> , <b>2001</b> , 158, 39-47	4.7	23
21	The Continuing Failure of Bexarotene in Alzheimer's Disease Mice. <i>Journal of Alzheimers Disease</i> , <b>2015</b> , 46, 471-82	4.3	20
20	Emmyloid oligomers and prion protein: Fatal attraction?. <i>Prion</i> , <b>2011</b> , 5, 10-5	2.3	20
19	Neuroprotective Effects of Doxycycline in the R6/2 Mouse Model of Huntington's Disease. <i>Molecular Neurobiology</i> , <b>2020</b> , 57, 1889-1903	6.2	20
18	Intranasal delivery of mesenchymal stem cell secretome repairs the brain of Alzheimer's mice. <i>Cell Death and Differentiation</i> , <b>2021</b> , 28, 203-218	12.7	20
17	Dopamine partial receptor agonists reduce ethanol intake in the rat. <i>European Journal of Pharmacology</i> , <b>1996</b> , 296, 233-8	5.3	18
16	Flavonoid-Derived Human Phenyl-EValerolactone Metabolites Selectively Detoxify Amyloid- Oligomers and Prevent Memory Impairment in a Mouse Model of Alzheimer's Disease. <i>Molecular Nutrition and Food Research</i> , <b>2020</b> , 64, e1900890	5.9	16
15	Biophysical and in Vivo Studies Identify a New Natural-Based Polyphenol, Counteracting All Oligomerization in Vitro and AlDligomer-Mediated Memory Impairment and Neuroinflammation in an Acute Mouse Model of Alzheimer's Disease. <i>ACS Chemical Neuroscience</i> , <b>2019</b> , 10, 4462-4475	5.7	14
14	A Rational Structured Epitope Defines a Distinct Subclass of Toxic Amyloid-beta Oligomers. <i>ACS Chemical Neuroscience</i> , <b>2018</b> , 9, 1591-1606	5.7	13
13	Pulmonary administration of functionalized nanoparticles significantly reduces beta-amyloid in the brain of an Alzheimer disease murine model. <i>Nano Research</i> , <b>2016</b> , 9, 2190-2201	10	13
12	The neurodegeneration in Alzheimer disease and the prion protein. <i>Prion</i> , <b>2013</b> , 7, 60-5	2.3	12
11	Gamma-hydroxybutyric acid decreases intravenous cocaine self-administration in rats. <i>Pharmacology Biochemistry and Behavior</i> , <b>1998</b> , 59, 697-702	3.9	12
10	Assessment of plaque morphology in Alzheimer's mouse cerebellum using three-dimensional X-ray phase-based virtual histology. <i>Scientific Reports</i> , <b>2020</b> , 10, 11233	4.9	8

## LIST OF PUBLICATIONS

9	The Anti-Prion Antibody 15B3 Detects Toxic Amyloid-Dligomers. <i>Journal of Alzheimers Disease</i> , <b>2016</b> , 53, 1485-97	4.3	8
8	Inflammation and Parkinson's disease pathogenesis: Mechanisms and therapeutic insight. <i>Progress in Molecular Biology and Translational Science</i> , <b>2021</b> , 177, 175-202	4	6
7	Internalization of nanopolymeric tracers does not alter characteristics of placental cells. <i>Journal of Cellular and Molecular Medicine</i> , <b>2016</b> , 20, 1036-48	5.6	4
6	Accelerating Alzheimer's disease drug discovery and development: what's the way forward?. <i>Expert Opinion on Drug Discovery</i> , <b>2021</b> , 16, 727-735	6.2	4
5	X-ray Phase Contrast Tomography Serves Preclinical Investigation of Neurodegenerative Diseases. <i>Frontiers in Neuroscience</i> , <b>2020</b> , 14, 584161	5.1	3
4	A critical appraisal of tau-targeting therapies for primary and secondary tauopathies. <i>Alzheimeris and Dementia</i> , <b>2021</b> ,	1.2	3
3	Deletion of calcineurin from astrocytes reproduces proteome signature of Alzheimer's disease and epilepsy and predisposes to seizures. <i>Cell Calcium</i> , <b>2021</b> , 100, 102480	4	2
2	Sleep inhibition induced by amyloid-libligomers is mediated by the cellular prion protein. <i>Journal of Sleep Research</i> , <b>2021</b> , 30, e13187	5.8	1
1	TLR4 in Neurodegenerative Diseases: Alzheimer and Parkinson Diseases. <i>Agents and Actions Supplements</i> , <b>2021</b> , 105-118	0.2	